Issue link: https://www.e-digitaleditions.com/i/1518209
Inhalation April 2024 33 Drug-device combinations targeting inhalation and nasal Recipharm offers a fully integrated, drug-device com- bination product service for developing and manu- facturing inhalation drug products and devices to the global pharmaceutical market, including pressurized metered dose inhalers (pMDIs), soft mist inhalers (SMI), dry powder inhalers (DPIs), unit-dose and multi-dose nasal sprays. By developing inhalation products with device and commercial manufacture in mind, we can eliminate hurdles and reduce time to market. Trust Recipharm to take your product from concept to commercialization and deliver expertise at every stage. Recipharm UK: +44 1553 691000 www.recipharm.com Inhaled and nasal drug delivery systems RxPack is a global leader in pharmaceutical dispens- ing solutions and inhaled nasal drug delivery systems. Specializing in pMDIs, RxPack offers a comprehen- sive valve portfolio for solutions and suspensions, for single or double-stage filling. e company supports its customers in navigating complex product devel- opment changes and the transition from the existing propellants to the new HFA 152a and HFA1234ze gases. RxPack partners with Coster's Machinery Division for the provision of lab-scale and high- speed filling lines. RxPack S.r.l. Italy: +39 034118960 info@rxpack.it www.rxpack.eu Dry powder inhalation capsule portfolio Lonza's Capsugel ® Zephyr™ dry powder inhalation (DPI) capsule portfolio is a comprehensive capsule product offering, featuring customized DPI capsules and dedicated equipment in place for efficient, phase- appropriate capsule filling. e Zephyr DPI portfolio addresses the need for highly customized solutions for pulmonary route delivery methods and is supported by Lonza's inhalation and drug development and par- ticle engineering capabilities. is integrated product and service offering can enable consistent and optimal release performance for inhalation drugs. Lonza Capsules & Health Ingredients US: +1 888 783-6361 www.capsugel.com Preclinical drug development Inhalation Sciences offers preclinical research ser- vices to obtain pharmacokinetic (PK) curves and dissolution data with an unprecedented level of accu- racy. is enables solid in vitro/in vivo correlations (IVIVC) and minimal translational errors, helping scientists make correct decisions about substances to send forward to clinical trials, small molecule drugs or biologics. For generic product development, Inhala- tion Sciences offers accurate dissolution profile com- parisons between test and reference substances with strong correlations to in vivo data. Inhalation Sciences Sweden: +46 70 562 5195 contact@inhalation.se www.inhalation.se